Current stock page

Stock Analysis

Eli Lilly and Company (LLY) Stock Analysis

Eli Lilly and Company (LLY) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

LLY Stock Analysis Summary

Eli Lilly and Company (LLY) currently has an AIQ Score of 43/100, indicating a neutral setup. Quality is the strongest factor at 76/100. Momentum is the weakest current factor at 23/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Sep 2, 2026 · Market-close data

LLY at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$1,165.59
AIQ Score43/100
Overall ViewNeutral
Technical Analysis ConsensusSell
Market Cap$1.14T
P/E Ratio38.57
Forward P/E
EPS$7.95
Revenue TTM$22.97B
Dividend Yield6.46%
Beta0.51
Volume862.85K
52-week range$712.05-$1,292.65
RSI 1439.58
50-Day SMA$1,189.16
200-Day SMA$1,061.33
Analyst Price Target$1,331.12
Next EarningsOct 29, 2026
As of Sep 2, 2026 · Market close
Free research limit

Create a free account to keep researching stocks

You have viewed 2 stock pages in the last 24 hours. Create a free account to keep researching current evidence.

LLY

Overview
Eli Lilly and Company
Healthcare· Drug Manufacturers - General
AIQ Score
NeutralAIQ Edge 3/10
Low Priority
Relative Laggard
Score data as of Sep 2, 2026
Last price
$1,165.59
+$5.59 (+0.48%)
Latest market quote
Momentum23
Value25
Quality76
Risk Resilience45
Sentiment
View financial data

LLY Stock Analysis Summary

Eli Lilly and Company (LLY) currently has an AIQ Score of 43/100/100, indicating a neutral setup. Quality is the strongest factor at 76/100/100. Momentum is the weakest current factor at 23/100/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Sep 2, 2026 · Market-close data
AIQ Composite Posture: Mixed

In a neutral regime, LLY has AIQ Score of 43/100 with Quality base of 76/100 and fading Momentum at 23/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Quality (76/100) leads while Momentum (23/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · 0.48% stock move · LLY classified in Drug Manufacturers - General.

Current Evidence

NeutralLLY is in a neutral AIQ regime; Quality is the strongest visible factor at 76/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is LLY Bullish or Bearish Right Now?

LLY currently has a neutral overall setup. Quality is the strongest factor at 76/100, while Momentum is weakest at 23/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.

Bull Case
  • - Quality is supportive at 76/100.
  • - Analyst target implies +14.20% upside from the latest quote.
Bear Case
  • - Value is the current constraint at 25/100.
  • - Momentum is weak at 23/100.
  • - Technical consensus has more sell votes than buy votes (28 vs 14).

Current Consensus

LLY's Technical Analysis Consensus is currently Sell, with 14 buy, 3 neutral, and 28 sell votes. LLY's 14-day RSI is 39.58, which places the stock in a weaker momentum range. LLY's beta is 0.51, indicating lower market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in LLY?

Recent score-change history is not available in the current snapshot. The page still shows the latest market-close evidence and timestamps.

AIQ Score
Momentum
Quality
Risk

What Would Change the LLY Outlook?

The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

LLY Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

LLY Fundamentals

LLY valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$22.97B
Net income
$7.1B
Free cash flow
$7.76B
View full LLY fundamental analysis

LLY Technical Analysis

LLY technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Sell
RSI 14
39.58
Price vs SMA-50
-1.98%
View full LLY technical analysis

LLY Stock Catalysts

Track LLY earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Oct 29, 2026
Analyst target
$1,331.12
News items
2
View LLY earnings and stock catalysts

LLY Dividend Analysis

LLY dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
6.46%
Annual dividend
$6.92
Payout ratio
View LLY dividend history and analysis

LLY Financial Data

LLY revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$22.97B
EPS
$7.95
Periods
8
View LLY financials

LLY Risk Analysis

LLY volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
0.51
Risk score
45/100
AIQ Score
43/100
View LLY risk analysis

LLY Stock News

LLY stock news, market tone, recent headlines, and catalyst context.

News items
2
Updated
Sep 2, 2026
Sentiment
Read LLY stock news

Popular LLY Comparisons

How LLY scores against the names it is most often compared with.

About the AIQ Score

Methodology for the current stock evidence.

As of Sep 2, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Sep 2, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Value and quality should explain the score, not sit behind it.

P/E
40.69
As of Sep 1, 2026
Revenue growth
16.04%
Gross margin
84.01%
Debt / equity
1.62
Latest quarterly evidence

Latest period Jun 30, 2026.

Review fundamentals
Quarter revenue
$22.97B
Quarter net income
$7.1B
Quarter free cash flow
$7.76B

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Mixed
Momentum
Bearish
RSI 14
39.58
MACD
-0.59

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
45/100
Beta
0.51
Annual volatility
35.89%
Max drawdown
-23.31%
Recent News
See all news
Sentiment —
No recent news found for LLY

Eli Lilly and Company (LLY) Stock Analysis

Snapshot summary of AIQ score, trend, and risk context.

Eli Lilly and Company has an AIQ Score of 43/100 in a Neutral regime. Quality is strongest at 76/100.

The main conflict is that quality leads at 76/100 while momentum lags at 23/100. Review the supporting factors together before drawing a conclusion from any single score.

Beta is 0.51, below market sensitivity. Current price is $1,165.59 and RSI (14) is 39.6.

Regime Context
LLY is in a Neutral AIQ regime with score 43/100.
Signal Conflict
The primary conflict is that quality leads at 76/100 while momentum lags at 23/100.
Factor Evidence
Momentum 23/100 · Value 25/100 · Quality 76/100 · Risk 45/100
Persistence
Current snapshot evidence is shown; historical persistence remains in AIQ Pro.
Factor strength
Pass
Quality is the strongest factor at 76/100.
Timing
Fail
Momentum is 23/100 and RSI (14) is 39.6.
Regime fit
Wait
LLY is in a Neutral regime at 43/100.
Risk control
Wait
Risk factor is 45/100 with beta 0.51 and annual volatility 35.89%.
Conflict
Wait
Current conflict: quality leads at 76/100 while momentum lags at 23/100.
AIQ Score43/100/100
Price$1,165.59
Beta0.51
RSI (14)39.6

Compare with Similar Stocks

See how LLY stacks up against its peers
Compare Stocks

Portfolio Implication

LLY currently shows balanced but still concentration-sensitive risk. Beta is 0.51, below market sensitivity.

LLY Stock FAQ

What is LLY stock price today?

Eli Lilly and Company's current stock price is $1,165.59. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is LLY bullish or bearish right now?

LLY's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is LLY's market cap?

LLY's market cap is $1.14T based on the latest completed market-close snapshot from Sep 2, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is LLY's current P/E ratio?

LLY's current P/E ratio is 38.57 based on the latest completed market-close snapshot from Sep 2, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is LLY's RSI?

LLY's 14-day RSI is 39.58 based on the latest completed market-close snapshot from Sep 2, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is LLY above its 50-day and 200-day moving averages?

LLY is -1.98% from its 50-day SMA and 9.82% from its 200-day SMA based on the latest completed market-close snapshot from Sep 2, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is LLY's next earnings date?

LLY's next earnings date is currently listed as Oct 29, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does LLY pay a dividend?

LLY's dividend yield is 6.46% based on the latest completed market-close snapshot from Sep 2, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.